16th Annual Cardiovascular Update Conference
February 6th and 7th from 8:00 am - 5:00 pm
For details visit: Registration Page

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • Third-Trimester Pregnancy Biomarkers Associated With Greater CV Risk
    Higher concentrations in the third trimester of the pregnancy-specific biomarker soluble fms-like tyrosine kinase-1 (sFlt-1) and the cardiovascular-specific biomarker high-sensitivity cardiac troponin I (hs-cTnI) were both independently associated with subsequent cardiovascular disease, according to research published Feb. 18 in JAMA Cardiology, suggesting that pregnancy may be a unique and important opportunity for cardiovascular risk assessment.
  • ACC CardiaCast: 2025 ACC Concise Clinical Guidance on Evaluation and Management of ATTR-CM
    In this podcast, Drs. Michelle Kittleson and Jan Griffin provide a practical overview of evaluation and management of transthyretin amyloid cardiomyopathy (ATTR-CM) based on ACC’s 2025 Concise Clinical Guidance document the Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.
  • REVELUTION: More Coronary Plaque Progression With Leuprolide Than Relugolix in Prostate Cancer
    In men with localized prostate cancer (PCa) treated with radiation and androgen-deprivation therapy (ADT), treatment with the gonadotropin-releasing hormone (GnRH) leuprolide was associated with a significant 12-month increase in coronary artery plaque volume when compared with treatment with relugolix, according to a brief report of the REVELUTION trial published Feb. 18 in JAMA.
  • 20-Year Outcomes For PVI in Patients With Drug-Refractory Paroxysmal AFib
    Twenty years after pulmonary vein isolation (PVI) during catheter ablation, stable sinus rhythm was maintained in a quarter of patients with symptomatic drug-refractory paroxysmal atrial fibrillation (PAF), including those taking antiarrhythmic drugs and those who had multiple ablation procedures, according to findings from a study published Feb. 17 in JACC: Clinical Electrophysiology.
  • Medtronic Clinician Update on New Evolut Valve Data Reinforces Need For Patient Dialogue
    Medtronic has issued a letter and developed web resources providing an update on long-term reintervention rates associated with its Evolut R and Evolut PRO transcatheter heart valves, drawing on complete six-year and partial seven-year follow-up data from the Evolut Low-Risk Trial published on Feb. 16 in JACC.